Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07819214 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI

Name: Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI — clinical trial record (NCT07819214)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorUniversity of California, Irvine

Started2026-10

View on ClinicalTrials.gov ↗

This is a phase 2, single-arm, open-label clinical trial determining efficacy of Epcoritamab in subjects with Chronic Lymphocytic Leukemia (CLL) on Burton Tyrosine Kinase Inhibitor (BTKi).

Trial Details

NCT Number	NCT07819214
Lead Sponsor	University of California, Irvine Collaborators: Genmab
Conditions	CLL, CLL (Chronic Lymphocytic Leukemia), Chronic Lymphocytic Leukemia (CLL), BTKi
Enrollment	24 participants
Start Date	2026-10
Primary Completion	2028-10 (estimated)
Study Completion	2032-10 (estimated)
Updated on ClinicalTrials.gov	2026-09-14